{"id":"NCT01114139","sponsor":"AMAG Pharmaceuticals, Inc.","briefTitle":"A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-19","primaryCompletion":"2012-02-27","completion":"2012-10-22","firstPosted":"2010-04-30","resultsPosted":"2018-06-11","lastUpdate":"2022-04-21"},"enrollment":812,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferumoxytol","otherNames":["Feraheme"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ferumoxytol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).","primaryOutcome":{"measure":"Participants Who Achieved A â‰¥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5","timeFrame":"Baseline (Day 1) through Week 5","effectByArm":[{"arm":"Ferumoxytol","deltaMin":252,"sd":null},{"arm":"Placebo","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":182,"countries":["United States","Canada","Hungary","India","Latvia","Poland"]},"refs":{"pmids":["23983177"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":608},"commonTop":["Headache","Nausea","Dizziness","Diarrhoea","Urinary Tract Infection"]}}